SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 13, 2022--
Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite, Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access. Dr. Leite’s responsibilities will include leading commercial activities for Veracyte’s lung portfolio, including market development for the noninvasive Percepta Nasal Swab test in lung cancer, in advance of its broad commercialization, as well as market access for the company’s CLIA portfolio. He will report to Tina Nova, Ph.D., president of Veracyte’s U.S. CLIA Lab business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005446/en/
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access (Photo: Business Wire)
“Veracyte is deeply committed to pulmonology where we believe there are significant unmet needs in lung cancer and other respiratory diseases that our tests can uniquely address,” said Dr. Nova. “We are thrilled for John Leite to lead our pulmonology franchise. We believe his deep diagnostics industry experience and leadership will be key to positioning Veracyte’s Percepta Nasal Swab test to make a major impact in the early evaluation of patients for lung cancer.”
Dr. Leite joined Veracyte from Intervenn, a private-stage diagnostics company where he was chief business officer, responsible for the company’s commercial, partnership and market access strategy. Prior to that he held leadership positions at Illumina from 2014 to 2020, where he initially served as vice president, Oncology, Market Development and Product Development, and then as vice president, Clinical Business Development. Prior to Illumina, he was vice president of Commercial Strategy and Market Access at Genoptix Medical Laboratories. Dr. Leite received his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biochemistry and Molecular Genetics at University of Pittsburgh, School of Medicine, and completed post-doctoral work as a National Research Service Award Fellow at the California Institute of Technology.
“Veracyte is a leader in providing high-value diagnostic tests that enable physicians and their patients to make better diagnoses and treatment decisions,” said Dr. Leite. “I’m excited to join the company and bring those benefits to the areas of lung cancer and interstitial lung diseases, where physicians often lack the information they need to provide optimal care for their patients.”
Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. In addition to making our tests available in the United States through our central laboratories, our exclusive license to our best-in-class diagnostics instrument (nCounter Analysis System) positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. An example of a forward-looking statement includes, among others, that we believe Percepta Nasal Swab will make a major impact in the early evaluation of patients for lung cancer. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q to be filed for the three months ended June 30, 2022. Copies of these documents, when available, may be found in the Investors section of our website at www.investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte, the Veracyte logo, Percepta and Envisia are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies used by Veracyte under license.
Veracyte delivers the Percepta Nasal Swab test and Envisia Genomic Classifier from its CLIA laboratories. Those tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for confirmation. This piece is distributed purely for educational purposes and is not intended to promote or encourage any off-label use of Veracyte products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005446/en/
Director, Investor Relations
Vice President of Global Corporate Communications
Source: Veracyte, Inc.